Pulmatrix completes dosing in pilot pharmacokinetic evaluation of PUR0200
Pulmatrix reported it has completed a pilot pharmacokinetic study of PUR0200 in healthy volunteers. PUR0200 is a dry powder, branded generic of a once-daily of a long-acting muscarinic antagonis for maintenance treatment of bronchospasm in patients with COPD. May 25, 2016